Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Eli Lilly & Co. (NYSE:LLY)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Upcoming Events
Sep 10Dividend payment of $0.28
Location
Lilly Corporate Center
Indianapolis, IN 46285
Phone: (317) 276-2000
Fax: (317) 276-3492
Employees (last reported count): 35,700
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Major Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Subsidiaries
 ·Divisions
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 500
Ownership
·Insider and 5%+ Owners: 17%
·Over the last 6 months:
 · 3 insider sells; 1.62M shares
  (0.8% of insider shares)
·Institutional: 68% (81% of float)
(1,909 institutions)
·Net Inst. Buying: 13.1M shares (+1.69%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Eli Lilly and Company discovers, develops, manufactures and sells products in one significant business segment, called Pharmaceutical Products. The Company also manufactures and sells animal health products, and manufactures and distributes its products through owned or leased facilities in the United States, Puerto Rico and 30 other countries. The Company's products are sold in approximately 160 countries. Eli Lilly directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The Company also conducts research to find products to treat diseases in animals, and to increase the efficiency of animal food production.
More from Market Guide: Expanded Business Description

Financial Summary
Eli Lilly and Co. is engaged in the discovery, development, manufacture and sale of pharmaceutical products. For the six months ended 6/30/01, net sales rose 15% to $5.84 billion. Net income rose 8% to $1.63 billion. Revenues reflect increased sales of Zyprexa, Gemzar, Evista and diabetes care products. Earnings were partially offset by the absence of $214 million in gains on sale of the joint venture between Lilly and EDS to WebMD.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Sidney Taurel, 52
Chairman, CEO, Pres
$6.1M$13M
Charles Golden, 54
CFO, Exec. VP, Director
2.4M--  
August Watanabe, M.D., 59
Exec. VP- Science and Technology
2.4M--  
John Lechleiter, 47
Exec. VP of Pharmaceutical Products and Corp. Devel.
--  --  
Gerhard Mayr, 54
Exec. VP, Pharmaceutical Operations
2.2M--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NYSE:LLYAs of 31-Aug-2001
Price and Volume
52-Week Low
on 6-Sep-2000
$66.625
Recent Price$77.63 
52-Week High
on 30-Nov-2000
$97.125
Beta0.34 
Daily Volume (3-month avg)2.73M
Daily Volume (10-day avg)2.80M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+6.8%
52-Week Change
relative to S&P500
+43.3%
Share-Related Items
Market Capitalization$87.3B
Shares Outstanding1.12B
Float932.9M
Dividends & Splits
Annual Dividend (indicated)$1.12 
Dividend Yield1.44%
Last Split: 2 for 1 on 16-Oct-1997
Per-Share Data
Book Value (mrq)$6.02 
Earnings (ttm)$2.90 
Earnings (mrq)$0.76 
Sales (ttm)$10.62 
Cash (mrq)$3.11 
Valuation Ratios
Price/Book (mrq)12.90 
Price/Earnings (ttm)26.72 
Price/Sales (ttm)7.31 
Income Statements
Sales (ttm)$11.6B
EBITDA (ttm)$4.70B
Income available to common (ttm)$3.18B
Profitability
Profit Margin (ttm)27.4%
Operating Margin (ttm)35.1%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)22.18%
Return on Equity (ttm)51.33%
Financial Strength
Current Ratio (mrq)1.39 
Debt/Equity (mrq)0.49 
Total Cash (mrq)$3.50B
Short Interest
As of 8-Aug-2001
Shares Short5.68M
Percent of Float0.6%
Shares Short
(Prior Month)
7.70M
Short Ratio2.17 
Daily Volume2.61M
See Profile Help for a description of each item above;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.